Dr. Clay Siegall is best known as the founder and CEO of Seattle Genetics. Seattle Genetics is a biotechnology company that specializes in innovative anti-body cancer therapy. It is a company where revolutionary science meets transformative cancer therapy. Dr. Siegall’s leadership of his pioneer company has lead to him being deemed a legend of targeted cancer therapies.
In just under two decades he has led the Seattle, Washington based firm to the pinnacle of the industry. It is responsible releasing the first anti-body drug conjugate approved by the FDA. Since it gained approval for the drug conjugate it has been developing over 20 drugs and at the same time is partnering with multiple drug manufacturers, including big names like Genentech and others.
Dr. Siegall and Seattle Genetics proves that hard work really does pay off. The company has come a long way since starting as a tiny startup with little funding and a handful of dedicated employees. And today no one can dispute that it is a major player in the cancer research space. With all Dr. Siegall has accomplished with the company it’s hard to believe he has even bigger plans for the future. He believes Seattle Genetics has the potential to make uninspired and stale cancer treatment obsolete.
About Dr. Clay Siegall
Dr. Siegall attended both the University of Maryland and George Washington University. He holds a Ph.D in genetics from the aforementioned. Before Dr. Siegall founded Seattle Genetics in 1998 he held various positions with multiple medical companies. He worked at the Bristol Myers Squibb Pharmaceutical Research Institute for six years until leaving to start his own company.
When you’ve had the kind of career Dr. Siegall has had you tend to earn a few awards. In 2012 he was the recipient of the Pacific Northwest Ernst & Young Entrepreneur of the Year.